Article Text

Download PDFPDF
Complete remission of ovarian endometrioid adenocarcinoma associated with hyperamylasemia and liver metastasis treated by paclitaxel and carboplatin chemotherapy: a case report
  1. T. Tohya*,
  2. S. Shimajiri,
  3. C. Onoda* and
  4. T. Yoshimura*
  1. * Department of Obstetrics and Gynecology, Kumamoto Rosai Hospital, Yatsushiro, Kumamoto, Japan
  2. Department of Pathology, Kumamoto Rosai Hospital, Yatsushiro, Kumamoto, Japan
  1. Address correspondence and reprint requests to: Toshimitsu Tohya, MD, Department of Obstetrics and Gynecology, Kumamoto Rosai Hospital, Yatsushiro, Kumamoto 866-8533, Japan. Email: tohya{at}fine.ocn.ne.jp

Abstract

Complete remission in the case of a 45-year-old woman with ovarian endometrioid adenocarcinoma associated with hyperamylasemia and liver metastasis is described. Ultrasound examination and CT scan revealed several large solid and cystic intra-abdominal tumors and a metastatic liver tumor. The serum amylase was 600μ/l (normal value: 60–200 μ/l), and electrophoresis identified isoamylases of the salivary type. A total abdominal hysterectomy with bilateral salpingo-oophorectomy was performed for invasive carcinoma of the left ovary. The histology of the left ovary showed endometrioid adenocarcinoma. Immunohistochemically, the adenocarcinoma cells were diffusely and strongly positive for amylase. The patient received six courses of paclitaxel and carboplatin combination chemotherapy. Two years later, the patient is alive and well, without evidence of disease. The prognosis of patients with ovarian cancer metastatic to the liver is uniformly poor. This represents the first report of complete remission of such a patient in the literature.

  • amylase
  • carboplatin
  • ovarian cancer
  • paclitaxel
  • pancreatitis

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.